Clinical Experience of 6 Cases of Primary Tubal Cancer

Turkish Journal of Pathology, 2009

followed by chemotherapy (1-5). In order to evaluate the clinicopathological characteristics, we retrospectively reviewed patients with primary cancer of the fallopian tube. In our study, a tumor has to fulfill some criteria to be diagnosed as a primary cancer of the fallopian tube (6). These include: ınTrODuCTıOn Primary tubal cancers are rare malignant tumors that account for approximately less than 1% of all gynecological malignancies. They are similar to those of epithelial ovarian cancer with their clinical features and risk factors. The management of fallopian tube cancer is similar to that of ovarian cancer, requiring cytoreductive surgery Öz Amaç: Primer tuba kanserleri, tüm jinekolojik sistem malignitelerinin %1'inden azını oluşturan nadir tümörlerdir. Bu çalışmada, anabilim dalımızda primer tuba kanseri tanısı almış, 20 olguyu retrospektif olarak inceleyerek, bu tümörlerin klinikopatolojik özelliklerini gözden geçirmeyi amaçladık. Gereç ve Yöntem: Bu çalışmada, Ocak 1997-Aralık 2005 tarihleri arasında, anabilim dalımızda primer tuba kanseri tanısı almış, 20 olgu gözden geçirildi. Bulgular: Hastaların yaşları 43-74 arasında değişmekteydi. 13 hastaya cerrahi evreleme operasyonu yapıldı. Olguların çoğu evre III olarak sınıflandırıldı. en sık histolojik tip seröz karsinomdu. Bir hastada eş zamanlı başka primer jinekolojik kanser mevcuttu. Tüm prognostik verilerine ulaştığımız 11 hastanın 9'unun cerrahi sonrası 16 ile 103 ay arası değişen oranda sağkalıma sahip oldukları izlendi. Sonuç olarak, primer tuba kanserleri histopatolojik özellikleri ile over karsinomlarına benzemekle birlikte, genellikle lenfatik ve peritoneal yayılımın izlendiği ileri evre tümörlerdir. Tedavi olarak sitoredüktif cerrahi ve kemoterapi uygulaması ile oldukça başarılı sonuçlar alınmaktadır. Sonuç: Jinekolojik tümörlerde detaylı ve iyi bir makroskopik inceleme ile bu nadir˝ tümörlerin sayısının artacağını düşünmekteyiz.

Libri Oncologici : Croatian Journal of Oncology, 2015

Surgery is the cornerstone of eff ective management of the ovarian, tubal and peritoneal cancer. In 2014 the International Federation of Gynecology and Obstetrics (FIGO) published a new classifi cation collectively covering cancer of ovary, fallopian tube and peritoneum as well as malignant ovarian germ cell tumors and malignant sex-cord stromal tumors. Comprehensive surgical staging according to the 2014 FIGO classifi cation system plays an important role in management of apparently early stage of ovarian, tubal and peritoneal cancer. Primary debulking (cytoreductive) surgery followed by paclitaxel and platinum based combination chemotherapy is the cornerstone of the advanced-stage disease treatment. In cases of suboptimal primary cytoreduction, interval debulking surgery performed after two to four cycles of chemotherapy based on the clinical judgment of the gynecologic oncologist is second att empt to achieve optimal cytoreduction. Secondary cytoreductive surgery can be considered in patients with platinum-sensitive locally recurrent ovarian cancer. The volume of residual tumor remaining after these surgical approaches is one of the most important independent prognostic factors for survival.

Geburtshilfe und Frauenheilkunde, 2015

Obstetrics & Gynecology, 2009

Synchronous primary ovarian and endometrial cancers are quite unusual based on our previous experience . Confirmative diagnosis depends on the pathologic recognition of different histologic patterns. Although some researchers have tried to determine the underlying mechanisms for the development of synchronous tumors using advanced molecular or clonal analysis, the etiologies of such tumors remain unclear . A recently proposed hypothesis suggests that the etiology of synchronous cancers is related to the embryologically similar organs that develop synchronous neoplasms when they are simultaneously subjected to carcinogens.

Gynecologic Oncology, 1973

Diagnostics, 2020

Ovarian cancer is the deadliest gynecologic malignancy, accounting for more than 14,000 deaths each year. With no established way to prevent or screen for it, the vast majority of cases are diagnosed as International Federation of Gynecology and Obstetrics (FIGO) stage III or higher. Individuals with germline BRCA mutations are at particularly high risk for epithelial ovarian cancer and have been the subject of many risk-reducing strategies. In the past ten years, studies looking at risk-reducing salpingo-oophorectomy (RRSO) in this population have uncovered an interesting association: up to 8% of women with BRCA1 or BRCA2 mutations who underwent RRSO had an associated serous tubal intraepithelial carcinoma (STIC). The importance of this finding is highlighted by the fact that up to 60% of ovarian cancer patients will also have an associated STIC. These studies have led to a paradigm shift that a subset of epithelial ovarian cancer originates not in the ovarian epithelium, but rathe...

International Journal of Gynecological Cancer, 2012

Objective: To describe the outcome of primary chemotherapy for women with advancedstage epithelial ovarian or primary peritoneal cancer and delayed surgery when optimal debulking surgery cannot be achieved at diagnosis. Methods: Between 1998 and 2006, we retrospectively reviewed the overall survival and examined prognostic markers in consecutive patients who were not suitable for initial radical surgery because of the extent of disease and/or poor performance status. They were treated with a policy of primary platinum-based chemotherapy, followed whenever possible in responding patients by debulking surgery. Results: A total of 171 patients received least one cycle of chemotherapy. Eighty-six patients proceeded to surgery and 53 (31% of 171 and 62% of 86) had optimal (G1 cm) residual disease. Eighty-five patients did not undergo surgery because they remained unfit or had not responded sufficiently to chemotherapy. The median overall survival was 18.7 months (95% confidence interval [CI], 16.5Y24.2). The median OS in the surgical group for optimal and suboptimal surgery was 40.8 (95% CI, 32.5Y50.0) and 22.5 (95% CI, 17.7Y37.1) months (P = 0.005). On multivariate analysis, interval surgery and optimal surgery were the only independent prognostic factors (hazard ratios, 0.45 and 0.43, respectively; P = 0.009). In the nonsurgical group, CA125 response was an independent prognostic factor (hazard ratio, 0.34; P = 0.001) with an OS of 21.7 months (95% CI, 14.0Y35.4) in women with a normal CA125 after treatment compared with 6.7 (95% CI, 4.5Y7.8) months. Conclusions: In one third of the women, the tumor was optimally debulked after primary chemotherapy and their median survival was 40.8 months. Suboptimal debulking surgery after primary chemotherapy did not result in a better survival than that achieved after a chemotherapy response alone, suggesting that surgery may be avoided when imaging after chemotherapy demonstrates residual disease that cannot be optimally debulked.

International Journal of Gynecology & Obstetrics, 2006

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017

The evolving knowledge of ovarian carcinogenesis sets the stage for our understanding of high-grade serous pelvic carcinoma (HGSC). Findings in prophylactic surgery introduced serous tubal intraepithelial carcinoma (STIC) as potential precursor of HGSC. The present study explores whether STIC instead should already be considered as an early stage of HGSC with a need for comprehensive staging and therapy. We identified all consecutive patients with HGSC who received first-line therapy in our referral center for gynecologic oncology from January 2011 to April 2016. All chemo-naive patients with upfront debulking surgery in whom an association of STIC and tumor lesions could be analyzed were included. Patients with previous removal of the adnexa or overgrown of the fallopian tube by the tumor were excluded. Pathological workup of the fallopian tubes according to the SEE-FIM protocol was conducted. We analyzed a series of 231 consecutive patients with HGSC of whom 121 (52.4%) had ovaria...

Annals of Medicine and Surgery, 2020

Introduction: Primary tubal cancer is very rare, most are diagnosed intra and post operatively. Histopathology is vital in determining the cancer origin. Here we present a case of fallopian tube cancer with clinical presentation mimicking endometrial origin. Case description: A 74-year old patient came with complaints of intermittent post-menopausal bleeding and pelvic pain. The patient had several investigations using Ultrasonography, Hysteroscopy-guided biopsy, and Magnetic Resonance Imaging. Pre-operative diagnosis was endometrial cancer based on histopathology of endometrial biopsy during hysteroscopy. Explorative laparotomy, total abdominal hysterectomy, bilateral salphingo-oophorectomy, pelvic and para-aortic lymph node dissection were then performed, and the tumor samples were sent to the histopathology laboratory. It was found that the post-operative diagnosis was in fact primary fallopian tube cancer stage IIB. Conclusion: For patients with gynecological malignancies, rare cases such as fallopian tube cancer should never be overlooked as a differential diagnosis.